No Need to Book Flights Right Away,
First, Give Your Life One More Authoritative Confirmation
Clinical-grade reconstruction of complex English and Malay medical records from Malaysian public hospitals (GH) or local private hospitals (Gleneagles / Pantai / SJMC / Sunway, etc.). Delivered point-to-point to discipline leaders at China's National Medical Centres;a legally valid written report co-signed by a multidisciplinary team is delivered within 5-7 working days.
Service & fee boundaries
One table: what is free, what USD 300 covers, and what it does not- Receipt and completeness check of submitted materials
- No specialist opinion issued; not an admission decision
- No fee and no obligation of any kind
- Medical record collection, English-Chinese medical translation and clinical restructuring (including pathology and imaging material)
- Submission and hospital coordination in China: routing to the right department and specialist team, appointment and record registration
- Written specialist review opinion (admission feasibility and treatment pathway guidance)
- Full refund under the stated terms if the case offers no treatment value or no clinical benefit
- Companionship inside the hospital, airport transfers and ground handling
- Travel, accommodation, visa and health check-up costs
- All medical fees charged by the hospital (paid by the patient directly to the hospital)
End of service：Once hospital coordination, appointment and record registration are complete, the platform service ends. Subsequent treatment, admission, tests and in-hospital communication in China are handled by the receiving hospital team, and the platform charges no further fees.
Why must a "Second Opinion" be obtained before travelling abroad?
Cross-border care is not only a financial decision; it is also a precious window to get ahead of the disease course. Flying to China without prior assessment may mean being unable to secure admission, following the wrong pathway and enduring severe physical strain.
Avoid Misdiagnosis and Staging Errors
Review of specimens by immunohistochemistry and next-generation sequencing (NGS) is essential. Leading pathology laboratories in China frequently revise the staging of rare mutations and false-positive nodules, preventing excessive or futile resection surgery.
Break Through Local Treatment Limits
When a Malaysian attending physician says that "standard treatment options have been exhausted", Chinese clinical centres often still offer a window for reversal through in-house novel targeted drugs, CAR-T cell immunotherapy and proton and heavy-ion radiotherapy.
Eliminate the Risk of Travelling Blind
Flying blindly to Beijing or Shanghai is very likely to be a wasted trip if the patient's PS score does not meet the threshold or there is no treatment indication. The second opinion issues a written admission decision and 100% confirms a bed and direct admission by the expert team.
Guide Your Local Attending Physician
Even if you ultimately decide not to travel, a stamped opinion from a leading cancer centre director allows specialists at Malaysian private hospitals (such as Beacon, Gleneagles or Sunway) to adjust local chemotherapy regimens directly.
MDT Clinical Second Opinion Report from a National Class A Tertiary Hospital in China
The standard deliverable includes translation and mapping of the original Malaysian English records, re-reading of raw DICOM images, a co-signed multidisciplinary plan and an assessment of admission feasibility in China.
Multi-Disciplinary Team Clinical Second Opinion Report
assignment_turned_inStructured Reconstruction Summary of the Original Malaysian English Reports
The patient presented to Kuala Lumpur General Hospital in April 2024 with a persistent dry cough. PET-CT showed a hypermetabolic soft-tissue mass in the right middle lobe (3.8×3.2cm) with multiple enlarged mediastinal lymph nodes, and brain MRI showed a single metastatic lesion in the left frontal lobe (0.8cm). The patient had already received first-generation targeted therapy (gefitinib) in Malaysia for 4 months and recently developed resistance progression with mild headache.
biotechSecond Assessment Findings on Pathology Slides and DICOM Imaging
• Imaging re-read: The primary lung lesion has enlarged compared with previous imaging (+22%); the frontal lobe nodule progressed from 0.8cm to 1.3cm with a mild surrounding oedema band.
• Molecular pathology review: Next-generation sequencing (NGS 680-gene large panel) performed by the Peking Union laboratory on the submitted Malaysian paraffin blocks confirmed EGFR exon 20 insertion (Exon 20ins), with high-level MET amplification (CNV=6.8). The original first-generation targeted drug is intrinsically insensitive.
psychologyMultidisciplinary Team (MDT) Consensus Treatment Plan
- •Systemic therapy: Discontinue the first-generation EGFR inhibitor. Escalation to an approved third-generation or bispecific antibody regimen in China is recommended (double-dose furmonertinib combined with the MET inhibitor savolitinib), which achieves a high objective response rate against Exon 20ins and MET pathway activation.
- •Management of the brain lesion: There is currently no indication for craniotomy for the left frontal metastasis. Precise stereotactic proton radiotherapy (SBRT/proton beam) is recommended first, achieving non-invasive local ablation while preserving cognitive function.
- •Expected benefit: The disease control rate (DCR) is estimated to reach 78%, and median progression-free survival (PFS) may be extended from the originally estimated 4 months to more than 14 months.
Standardized 4-Step Delivery Workflow Loop
Stay in Malaysia without leaving home and connect directly to China's leading medical expert pool through a professional medical bridge.
Submission and Medical Intake
The family or the patient submits the original English/Malay discharge summaries and pathology reports from Malaysian hospitals online, and sends the original lossless DICOM image files by courier or direct cloud upload.
China-Malaysia Clinical-Grade Reconstruction
A China-Malaysia bilingual licensed medical team performs clinical-grade translation and terminology mapping, restructuring the Malaysian records into the admission record and structured summary that meet National Health Commission standards.
Targeted Review by Leading Class A Tertiary Experts
Cases are submitted point-to-point to expert panels at national medical centres such as Peking Union, Fudan Cancer and Sun Yat-sen Cancer. Closed-door image reading, second assessment of gene mutations and multidisciplinary consultation are then carried out.
Report Issuance and Bilingual Interpretation
A written opinion bearing the hospital's official seal and the experts' signatures is delivered. A senior China-Malaysia medical consultant then arranges a 45-minute one-to-one phone/video interpretation session to fully set out the next steps for the family.
Completely Transparent Pricing,
A Second Opinion With Genuine Peace of Mind
We fully understand the psychological and financial pressure on families facing critical illness. YILV CHINA maintains a "zero-risk trial" mechanism: a very low threshold in exchange for authoritative national-level assessment, with no hidden charges or intermediary mark-ups.
100% clinical-grade reconstruction of the full record set in Chinese and English: no need for the family to engage a separate commercial translation agency; a professional clinical team handles everything.
Direct access to senior directors at national-level specialty centres: review is never delegated to general physicians, ensuring the report is assessed and signed personally by discipline leaders.
Admission feasibility and precise costing of the whole journey: the report also includes direct flight planning to China, visa guidance and a precise estimate of treatment costs in China.
Includes record collection, English-Chinese medical translation and clinical restructuring (including pathology and imaging material), submission and coordination with the right department at a Chinese Grade 3A hospital including appointment and record registration, and a written specialist review opinion with a 1-to-1 interpretation.
If the expert panel jointly determines that the condition is in an irreversible terminal stage and that no plan with clinical benefit can be provided, a full refund is guaranteed.
This $300 USD covers three things: record restructuring, specialist review and submission/hospital coordination. Once hospital coordination and appointment/record registration are complete, the platform service ends; subsequent treatment in China is handled by the receiving hospital team and the platform charges no further fees (companionship, ground handling, travel, accommodation, visa, check-up and hospital medical fees are all excluded).
Answers to Common Questions About Second Opinions
Remove communication concerns and make responsible decisions for life based on objective medical evidence.
Will my local Malaysian attending doctor mind that I seek a "second opinion"?expand_more
I only have the Malaysian English reports and a local disc. Do I need to find a translation agency myself?expand_more
After I receive the second opinion report, will it be useful to me if I do not go to China?expand_more
The turnaround is 5-7 working days. Can I request an expedited service for a critical or severe case?expand_more
Submit Records · Free Preliminary Feasibility Review and Second Opinion Booking
Please fill in the information below. A bilingual China-Malaysia licensed case coordinator will contact you via WhatsApp within 4 hours to follow up.